IntroductionAntiretroviral therapy (ART) for HIV/AIDS is associated with adverse events (AEs). However, little is known about the differences in the risk of AEs between women and men living with HIV/AIDS. This study aims to determine (1) whether there are sex differences in the risk of AEs in people with HIV/AIDS treated with ART and (2) the prevalence of AEs to the reproductive system and bone mineral density in women.Methods and analysisThis systematic review (SR) will include randomised trials evaluating ART in people living with HIV/AIDS with at least 12 weeks of duration follow-up. Searches will be conducted in Medline, Embase, Cochrane Library, Epistemonikos, Lilacs, trial registries and grey literature databases, without restriction on publication status, year of publication and language. The primary outcome will be the risk of ART discontinuation or drop-outs/withdrawals of ART due to AEs and the number of any treatment-emergent AE. The secondary outcomes are the incidence of serious clinic or laboratory (grade 3 and/or 4) treatment-emergent AEs, hospitalisation, death and AEs specific to the reproductive system and bone mineral density (osteoporosis, osteopenia and fractures) of women. Selection, data extraction and quality assessment will be performed by pairs of reviewers. Cochrane collaboration tools will be used to assess the risk of bias. If appropriate, a meta-analysis will be conducted to synthesise results. The overall quality of the evidence for each outcome will be determined by the Grades of Recommendation, Assessment, Development and Evaluation.Ethics and disseminationThe results of this SR will assist the formulation of public policies aimed at the management and monitoring of AEs of ART in people living with HIV/AIDS. A deliberative dialogue will be scheduled with the Department of Chronic Conditions and Sexually Transmitted Infections of Brazil’s Ministry of Health to align the project with policymakers’ interests.PROSPERO registration numberCRD42021251051.

No abstract

Objectives: Determine the prevalence and predictive factors of low back pain and workrelated musculoskeletal disorders in Brazilian domestics and cleaners. Methods: This population-based cross-sectional study collected data from the 2013 and 2019 National Health Survey, involving a total of 8,160 workers. The prevalence of low back pain and work-related musculoskeletal disorders was calculated based on adjusted prevalence ratio (PR) by Poisson regression and 95% confidence interval (95%CI). Results: The prevalence of low back pain was 19.1% in 2013 and 20.6% in 2019; while musculoskeletal disorders prevalence was 2.2% in 2013 and 2.4% in 2019. Low back pain was associated with the elderly (PR: 1.74; CI95%: 1.44-2.09), poor or very poor self-rated health (PR: 2.10; CI95%: 1.76-2.50), holding a prepaid health plan (PR: 1.27; CI95%: 1.09-1.47) and moderately severe (PR: 2.27; CI95%: 1.84-2.80) or severe (PR: 2.32; CI95%: 1.77-3.04) depressive symptoms. Musculoskeletal disorders affected less domestics (PR: 0.53; CI95% 0.40-0.72); and were associated to women (PR: 2.50; CI95%: 1.34-4.66), adults (40-59 years) (PR: 1.79; CI95%:1.26-2.55), holding a prepaid health plan (PR: 2.31; CI95%: 1.63-3.26) and the presence of moderately severe (PR: 4.00; CI95%: 2.34-6.86) or severe (PR: 3.63; CI95%: 1.77-7.46) depressive symptoms. Conclusion: Domestics and cleaners Brazilian need interventions and health improvementsgiven the prevalence of low back pain and musculoskeletal disorders as well as their association with depression.

Objective: This systematic review analyzed the effectiveness and the safety of oral corticosteroids in the treatment of rheumatoid arthritis. Method: The search sources were Cochrane (CENTRAL), MEDLINE, EMBASE, CINAHL, Web of Science, among other; in order to identify randomized controlled trials (RCT) that compared the oral use of corticosteroids to placebo or other treatments in adults. Reviewers, in pairs and independently, selected studies, performed data extraction and assessed the risk of bias. Narrative synthesis of data was performed. Results: Thirteen RCT were selected (n=2,393 patients) and more than 50% of them had some risk of bias. Prednisone 5mg and prednisolone 7.5mg seem to improve pain. Physical function improved with the use of prednisone 5mg, 10mg plus methotrexate (MTX) and 30mg plus MTX; and use of prednisolone 5mg, 7.5mg plus disease modifying anti-rheumatic drugs (DMARD). Prednisone 10mg and prednisolone 5mg, 7.5mg, 30mg and 60mg (alone or with DMARD) seems to improve radiological imaging. Prednisone 5mg and prednisolone 7.5mg reduced morning stiffness. Prednisone 5mg and 10mg (plus aurothioglucose), and prednisolone 7.5mg, budesonide 9mg seem to reduce the number swollen joints. Prednisone 5mg and 10mg, prednisolone 5mg and 7.5mg, and budesonide 9mg reduced the number tender joints. Prednisone 10mg and prednisolone 5mg improved grip strength. Prednisone 5mg, prednisolone (plus MTX and ciclosporin) and prednisolone 7.5mg improved quality of life. Prednisolone and budesonide showed larger numbers of common and serious adverse events. Conclusion: Prednisone 5mg and 10mg and prednisolone 5mg and 7.5mg seems to be effective, while prednisone appears to be safer anti-inflammatory to the treatment of rheumatoid arthritis. However, methodological limitations and the combination of different drugs and doses, contributed to limiting the conclusions on these findings.